An overview of biosimilars for IBD in 2022. Also, the positioning of advanced therapies for Ulcerative Colitis and Crohn's disease based on efficacy data, and a new "safety pyramid."
This session is supported by an independent educational grant from Amgen, Inc.
Learning Objectives:
Evaluate the most recent clinical data associated with biosimilars for the management of IBD
Consider the approval process that ensures the efficacy and safety of biosimilars